Suppr超能文献

复方新诺明的微生物学观点

Microbiological perspectives of co-trimoxazole.

作者信息

Bauernfeind A, Hörl G, Przyklenk B

机构信息

Max von Pettenkofer Institute, University of Munich.

出版信息

Infection. 1987;15 Suppl 5:S232-5. doi: 10.1007/BF01643195.

Abstract

Trimethoprim-sulfamethoxazole in vitro activity was compared with ampicillin, tetracycline, sulfonamide and trimethoprim against isolates of 24 gram-negative and 11 gram-positive species. The incidence of more than 10% of strains with minimal inhibitory concentrations above 32 mg/l was restricted to Escherichia coli, Shigella spp., Klebsiella pneumoniae, Providencia rettgeri, Morganella morganii, methicillin-resistant Staphylococcus aureus and Staphylococcus epidermidis. Occasionally, Streptococcus pneumoniae and Haemophilus influenzae strains with MICs above 32 mg/l were identified. Co-trimoxazole in vitro activity was superior to the comparative drugs for the majority of species. Co-trimoxazole remains an active combination against major pathogens of infections of the upper and lower respiratory, urinary tract and enteric infections with a still low incidence of resistant organisms.

摘要

将甲氧苄啶-磺胺甲恶唑的体外活性与氨苄西林、四环素、磺胺类药物和甲氧苄啶针对24种革兰氏阴性菌和11种革兰氏阳性菌的分离株进行了比较。最低抑菌浓度高于32mg/l的菌株发生率超过10%的情况仅限于大肠杆菌、志贺氏菌属、肺炎克雷伯菌、雷氏普罗威登斯菌、摩根氏摩根菌、耐甲氧西林金黄色葡萄球菌和表皮葡萄球菌。偶尔也会鉴定出最低抑菌浓度高于32mg/l的肺炎链球菌和流感嗜血杆菌菌株。对于大多数菌种,复方新诺明的体外活性优于对照药物。复方新诺明仍然是针对上、下呼吸道感染、尿路感染和肠道感染的主要病原体的一种活性组合,耐药菌的发生率仍然较低。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验